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Extracampine hallucinations (EH), the sense of a presence or fleeting movement in the 
absence of an associated visual percept, have been reported in Parkinson’s disease 
(PD) patients but their prevalence, characteristics, and temporal relationship to visual 
hallucinations (VH) remain unclear. Given that, VH are predictive of cognitive impairment 
in PD, improved understanding of EH may have significant prognostic implications. The 
objective of this study is to evaluate the prevalence and characteristics of EH in a large 
unselected population with PD and to assess the temporal relationship between EH, 
VH, and memory decline. Cross-sectional data were collected from 414 PD patients 
using a questionnaire circulated via an online patient community. Data were obtained 
regarding the occurrence, timing, and characteristics of VH and EH and symptoms of 
PD, disease duration, disease severity, and medication history. About 50.4% of respon-
dents reported EH and 15.5% reported VH. EH were typically experienced alongside, 
rather than behind, the individual (p < 0.001) without clear lateralization (p = 0.438) and 
were more likely to be of unfamiliar presences (p < 0.001). The occurrence of EH was 
associated with Hoehn and Yahr score (p = 0.002) but not disease duration (p = 0.158). 
EH onset was associated with VH onset (p = 0.046) and occurred after the onset of 
anosmia (p < 0.001), cognitive decline (p = 0.002), and sleep disturbance (p = 0.002). 
The reported prevalence of EH in PD patients was threefold greater than that of VH, with 
similar timings of onset, suggesting that EH are under-recognized and under-reported. 
Further work is needed to determine whether EH are predictive of cognitive decline.
Keywords: Parkinson’s disease, hallucinations, extracampine hallucinations, cortical lewy body disease, visual 
hallucinations
inTrODUcTiOn
Hallucinations, defined as “sensory perceptions without external stimulation of the relevant sensory 
organ” (1), are a common feature of Parkinson’s disease (PD) and are a poor prognostic marker 
associated with increased risk of nursing home placement and cognitive decline (2, 3). Various types 
of hallucinations have been described in PD, including formed visual hallucinations (VH), auditory 
hallucinations, and extracampine hallucinations (EH), the latter denoting hallucinations occurring 
outside the visual field (campus, from Latin, field) (4, 5).
Of these hallucinations, VH are the most commonly described with the lifetime prevalence in 
PD patients approaching 75% (6). The presence of VH is typically a late feature of PD (4, 7) and is 
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predictive of cortical Lewy body pathology at post-mortem (8, 
9). VH in PD are associated with the occurrence of cognitive 
dysfunction, daytime somnolence, and sleep disorders (4, 10, 11). 
Although their neural basis is not yet fully established, structural 
and functional neuroimaging studies have implicated a variety 
of brain systems, including anterior visual pathways, brainstem, 
and visual association regions in their pathogenesis (12). More 
specifically, evidence suggests a role for altered cortical visual 
processing in the pathogenesis of VH in PD (13).
In addition, antiparkinsonian drug therapy has been reported 
to precipitate psychosis (14, 15) with certain drugs, particularly 
dopamine agonists, being linked to VH in PD (16). However, 
dopaminergic drug use is not sufficient to explain the occurrence 
of all VH in PD (4). Furthermore, drug-induced psychosis in PD 
may persist even when the offending medication is withdrawn 
(17), and there appears to be a poor correlation between drug 
exposure and symptom severity (18).
In contrast to VH, EH (5) are not associated with any visual 
percept. Instead, EH are experienced as the sense of a presence 
beside or behind, or as a fleeting sense of movement alongside, 
the individual perceiving this phenomenon. In previous studies 
of hallucinoses associated with PD, EH have been classified as 
“minor hallucinations,” which, when combined with illusions, is 
associated with a prevalence ranging from 17 to 72% (4, 19–21). 
Several explanations exist for this wide range in reported 
prevalence, including heterogeneity of study populations and 
methodological differences in assessing the presence of these 
symptoms (21).
The occurrence of EH is not specific to PD; they have been 
reported in cerebrovascular disease, epilepsy, sleep paralysis, 
and traumatic brain injury (22–24). Aside from neurological 
disorders, EH have been described by individuals in  situations 
associated with extreme physical hardship, such as shipwreck 
survivors, mountaineers, and polar explorers (25–27), perhaps 
most famously by Ernest Shackleton during his failed Antarctic 
expedition of 1914–1917.
...  it seemed to me often that we were four, not three. 
I said nothing to my companions on the point, but 
afterwards Worsley said to me, ‘Boss, I had the curious 
feeling on the march that there was another person with 
us’ (25)
In the context of neurodegenerative diseases, the presence of 
VH is a relatively specific feature of cortical Lewy body disease 
(9, 28) and forms one component of the diagnostic criteria for 
Dementia with Lewy Bodies (DLB) and Parkinson’s Disease 
Dementia (8, 29). Given that, VH are predictive of future cogni-
tive decline (30–32), it is possible that other types of hallucinosis 
may also have predictive value, notably those likely to be indica-
tive of cortical involvement.
Extracampine hallucinations are by definition less overt than 
VH, and therefore may be both under-reported by patients and 
under-investigated by clinicians, who do not routinely include 
questions about EH in their history taking (5). Additionally, 
while the neural substrate of EH has yet to be clarified, their phe-
nomenological nature would implicate higher order association 
cortices in EH generation beyond any reasonable doubt. As such, 
it is important to establish whether EH represent a cortical marker 
of disease in patients with PD, and thus are predictive of future 
cognitive and clinical decline. Such determination would have 
major implications for biomedical research, in terms of disease 
phenotyping and natural history studies, and for clinical practice, 
with the assessment of EH in patients with PD potentially acting 
as a prognostic marker alerting clinicians to impend cognitive 
decline. In practice, EH focused questions could be included in 
the routine clinical history or, in the future, could be assessed in 
specialist PD clinics using a validated EH questionnaire similar to 
those currently in use for the assessment of VH (33).
However, prior to any such studies, the first step is to obtain a 
better understanding of the occurrence of EH in patients with PD, 
in view of the limited information available at present. The primary 
objective of this study was therefore to determine the prevalence 
of EH in patients with PD. The secondary objectives are to identify 
the main characteristics of EH (for example, emotional content, 
familiarity of percept, laterality of EH) and to assess the temporal 
relationship between the onset of EH and other key symptoms 
of PD, specifically VH, cognitive impairment, and REM sleep 
behavior disorders. In order to obtain these data from a more 
representative sample of PD patients, and thus offset the potential 
ascertainment bias associated with sampling from a specialist PD 
clinics, information about EH occurrence were acquired by way 
of a web-based questionnaire made available to an online social 
networking community of patients, patientslikeme® (34).
MaTerials anD MeThODs
recruitment and administration of 
Questionnaire
patientslikeme® is an online patient network where members 
share personal health data to track their disease progression, 
communicate with other patients, and contribute to research 
studies. Members of the community are regularly invited to 
participate in optional questionnaire-based research studies 
(34). Although patients with any illness are able to sign up to 
the website, patientslikeme® has a large online community of 
individuals with PD; at the time of this study, there were 6841 
such members.
All members of the patientslikeme® community who had 
previously self-identified as having PD were invited to partici-
pate in the study via email (Figure 1). The link provided in the 
email enabled potential participants to access the study infor-
mation and indicate whether or not they wished to participate. 
Submission of the completed questionnaire was interpreted as 
provision of consent for study enrollment in line with ethical 
guidelines from The University of Sussex on the acquisition of 
anonymous questionnaire-based data from patient groups (35). 
The online survey remained open for 1 week and to verify the 
test–retest reliability of the EH questionnaire and, in line with 
routine practice in questionnaire-based surveys hosted on the 
patientslikeme® platform, all participants were invited by email 
to complete a retest phase 2  weeks later in which an identical 
questionnaire was administered.
FigUre 1 | Flowchart illustrating the recruitment and progression of 
participants through the study.
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ethics
Ethical approval for this study was obtained from the South East 
Coast  –  Surrey Regional Ethics Committee (reference number 
12/LO/1001).
inclusion/exclusion criteria
Those included in the study were adults with a self-reported 
diagnosis of PD. Respondents were excluded if they had self-
reported Lewy body dementia, PD with associated dementia, 
a non-PD neurodegenerative disorder, or moderate-to-severe 
visual impairment (cataracts, macular degeneration, diabetic eye 
disease, or registered blind).
Questionnaire
The study instrument was a novel, web-based, questionnaire, 
which was completed via the patientslikeme® online platform. 
The questions were generated by the study authors with input 
from patients with PD and their caregivers. Participants were 
informed of the nature of the study in terms of the information 
being requested but were blinded to the specific hypotheses being 
tested, in order to eliminate reporting bias. In order to increase the 
response rate, an email reminder was sent after the initial launch.
All data were self-reported and information was gathered 
regarding demographics, co-morbidities, and current and previ-
ous experiences of illusions (Q1,Table  1), VH (Q22–26), and 
EH (Q2–21). Two questions were used to assess whether or not 
participants had experienced EH (Q2 and Q6) and a participant 
was defined as having had an EH if they answered yes to one or 
both of these questions.
Participants were asked to characterize EH in terms of EH 
location relative to themselves (Q3), laterality (Q4), emotional 
content (Q28), time of day of occurrence (Q5), form (Q7), and 
familiarity (Q8). They were also asked about any auditory or 
tactile (Q9–10) components, whether their EH were stereotyped 
(Q11) and the effect of medications on their EH, in terms of 
aggravation or amelioration (Q12–14). All known trade names 
for PD medications were used, to help ensure correct identi-
fication of medications used by participants from different 
countries.
Data were also collected regarding the relationship between 
the onset of EH and other features of disease, such as VH, memory 
decline, anosmia, and sleep disturbance. Disease severity was 
assessed using a modified version of the Hoehn and Yahr score, 
already in use by patientslikeme®, in which patients identify their 
disease severity (Table 1).
statistical analysis
Statistical analysis was performed using IBM SPSS Statistics 
Version 22.0. Descriptive statistics were used to analyze the 
characteristics of EH in terms of laterality (left/right), familiarity 
(familiar/unfamiliar), emotional content (pleasant/unpleasant/
neither), associated emotional response (happy/sad/neither), and 
time of day (morning/afternoon/evening/night). Chi-squared 
testing was undertaken to determine whether there were signifi-
cant differences between the expected and observed frequencies 
of these variables.
Respondents were divided into two groups, those with EH 
and those without, and the distribution of variables, such as 
age, gender, disease duration, and severity and presence of 
VH within these groups were compared using an independ-
ent t-test, Mann–Whitney U, or a chi-squared test (with or 
without trend) depending on whether the variable being 
analyzed was continuous or categorical and normally distrib-
uted. Normality of data was assessed using visual inspection 
of histograms, QQ plots and box plots, and Shapiro–Wilk 
testing.
A logistic regression analysis was undertaken to determine 
if a set of pre-specified variables (age, gender, disease duration, 
disease severity as specified by Hoehn and Yahr score, and 
presence of VH) were predictive of the occurrence of EH (36). 
These potential predictor variables were selected based on prior 
clinical knowledge and pre-specified hypotheses, explicitly that 
the prevalence of EH would not be influenced by demographic 
factors, such as age and sex, but would be affected by disease dura-
tion, disease severity, and VH, putative correlates of accumulat-
ing cortical Lewy Body pathology. A Box–Tidwell test was used 
to ensure there was linearity for continuous and transformed 
categorical variables. The dependent variable, the occurrence of 
EH, was dichotomous and assigned a value of 1 (EH occurrence) 
or 0 (no EH occurrence).
resUlTs
recruitment
Data from 414 respondents were included in the study. Of the 
6841 individuals with PD who were invited to participate, 569 
responded indicating a response rate of 8.3%. Forty (9.7%) 
respondents were excluded as they had not completed the 
questionnaire, and 115 (20.2%) were excluded on the basis of the 
exclusion criteria outlined above.
Participant Demographics
The mean age of respondents was 61.9  years (standard devia-
tion 8.2  years, range 33–88  years) and 48.2% (199/413) of the 
cohort were female. About 83.5% (324/388) of participants were 
TaBle 1 | Questionnaire items as posed to participants.
Modified Hoehn 
and Yahr score
Parkinson’s disease progresses through five stages, called “Hoehn and Yahr” stages. Please indicate which of the five statements below best 
describes your status at the moment
 1. I have symptoms on one side of my body only
 2. I have symptoms on both sides of my body but no problems with balance or walking
 3. I’m having problems with my balance and walking
 4. I can still stand and walk but with great difficulty
 5. I cannot stand or walk independently; I need help or a wheelchair
Illusions   Q1.  Have you ever looked at something and thought it was something else altogether?  
(For example: spots on the wall looking like insects or a lampshade cover being mistaken for a person.) Yes/No
EH: feeling of a 
movement
  Q2.  Have you ever experienced a feeling of movement past you when there was nothing there to account for this feeling?  
(Some patients report a sensation that something has flashed past them, out of the corner of their eyes.) Yes/No
  Q3. Where was the feeling of movement in relation to you? Front/Behind/To the side
  Q4.  If to the side, do they occur more on the left or the right?  
Mostly on the left/Mostly on the right/There is no pattern/I have not noticed a pattern/Does not apply
  Q5. Are these experiences more common at a particular time of day? Morning/Afternoon/Evening/Night/There is no pattern
EH: feeling of a 
presence
  Q6. Have you ever felt of imagined a presence either behind or alongside you when there was nothing there to account for this feeling? Yes/No
  Q7. Do you feel as though this presence is human, animal or other? Human/Animal/Other
  Q8. Is the presence familiar to you? Yes/No
  Q9. Does the presence ever speak to you or make another noise? Yes/No
Q10. Does the presence ever touch you? Yes/No
Q11. Are these experiences always the same? Yes/No
Q12. Have any of your medications ever made these experiences better OR worse? Yes/No
Q13.  If you have ever taken any of the following medications* please indicate how they affected these experiences.  
Improved symptoms/Worsened symptoms/No effect on my symptoms/I have never taken this medication
Q14.  If you have ever taken any other medications for your Parkinson’s disease, please indicate what these were and how they affected these 
experiences
Q15. Do you have a reduced sense of smell? Yes/No
Q16. Have you noticed a decline in your memory or thinking? Yes/No
Q17. Have you noticed a change in your ability to walk or maintain balance? Yes/No
Q18.  Have you noticed that your sleeping has become more restless or disturbed? Yes/No
For questions 15–18, if the answer was yes participants were also asked
Q19. Did you notice this before or after you FIRST noticed the presence? Before/After
Q20. Are you able to estimate how much time passed between noticing this and first becoming aware of a presence? Yes, I can/No, I cannot
Q21. If yes, please estimate this period (in days, weeks, months, or years)
VH Q22.  Have you ever SEEN things that were not really present or that other people could not see?  
(For example, some patients report seeing animals or children that others cannot see.) Yes/No
Q23.  If you answered YES, when did this occur in relation to feeling/imaging the sense of a presence?  
Before/After/They occurred at the same time/I am not sure which occurred first
Q24. If you answered BEFORE or AFTER please estimate this period (in days, weeks, months or years)
Q25.  How often do you see things that are not really present or that other people cannot see?  
Less than once a week/At least once a week/Several times a week
Q26.  What do you generally see during these episodes? The images are not fully formed/I see adult beings/I see children/I see animals or 
insects/I see shadows that may sometimes move/I see other everyday objects
For each type of hallucination (eh and Vh) the following questions were asked
Q27.  When was the last time this happened? Within the last week/Within the last month/Within the last 3 months/Within the last 6 months/More 
than 6 months ago
Q28. These experiences are: Pleasant or reassuring/Unpleasant or frightening/Neither
Q29. These experiences make me feel: Happy/Sad/Neither
Sleep Q30. I sometimes have very vivid dreams Yes/No
Q31. I have been told that I kick and/or punch in my sleep Yes/No
Q32. I have been told that I shout, swear or laugh in my sleep Yes/No
In addition to the potential responses listed, participants were also able to skip the question.
*Co-careldopa, Co-benyldopa, Stalevo, Rotigotine, Pramipexole, Ropinirole, Benzotropine, Trihexyphenidyl, Selegiline, Rasagiline, Entacapone, Amantadine, Rivastigmine, Donepezil, 
Galantamine.
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resident in the United States or United Kingdom with others 
living in Europe, Canada, Australasia, South America, and the 
Middle East. The mean Hoehn and Yahr score was 2.11 (SD 0.99, 
range 1–5) with 94.9% (391/412) of participants reporting a 
score between 1 and 3. Mean disease duration was 7.3 years (SD 
5.0 years, range 1–29 years).
Prevalence of hallucinations
About 33.9% (140/413) of respondents reported illusions 
and 15.5% (64/412) had experienced VH. More than half of 
respondents reported EH; 45.9% (190/414) reported a “feeling of 
movement” passing them and 24.6% (102/414) reported “feeling 
or imaging a presence that was not truly there.” Given that, 20.3% 
FigUre 2 | Prevalence of hallucinations. (a) Extracampine hallucinations (EH), “feeling or imagining a presence” versus a “feeling of movement”; (B) Prevalence 
of EH and visual hallucinations (VH).
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reported both symptoms, 50.4% (208/413) experienced either 
a “feeling of movement” or had “felt or imagined a presence” 
(Figure 2).
Predictors of eh
Neither age nor gender was predictors for the occurrence of 
EH (Table 2). Mean disease duration did not differ significantly 
between the EH and non-EH groups (p = 0.158), but those with 
EH were more likely to have a higher Hoehn and Yahr Stage 
(p = 0.002) (Table 2).
characteristics of eh
Extracampine hallucinations were more likely to occur alongside 
rather than directly in front of or behind the person experiencing 
them (p < 0.001) (Table 3). Although EH did lateralize to the left 
or right in 47.0% (78/166) of cases this was a non-significant find-
ing (p = 0.438) with a similar proportion of respondents (53.0%, 
88/166) stating either that there was no left/right pattern or that 
they had not noticed such a pattern. Of the 47.0% (78/166) that 
did lateralize more were reported on the right side but this did not 
reach statistical significance (p = 0.070).
Extracampine hallucinations were more likely to feel “unfa-
miliar” than “familiar” (p = 0.001) and seemed to be emotional 
neutral experiences making people feel neither happy nor sad 
(p < 0.001), and neither pleasant nor unpleasant, whether they 
had reported “a feeling of movement” (p < 0.001) or the “sense of 
a presence” (p < 0.001) (Table 3).
Timing of eh
In those who reported EH these were often recently experienced; 
81.6% (151/185) of those who reported a “feeling of a movement 
passing them” and 72.3% (73/101) of those who reported a 
“felt or imagined presence” had experienced this phenomenon 
within the previous three months. EH were not associated with 
a particular time of day (morning/afternoon/evening/night) 
(p < 0.001).
relationship Between eh and Other 
symptoms associated with PD
Extracampine hallucinations co-existed with other PD symptoms. 
Of those who reported EH, 75.5% (77/102) also had anosmia, 
73.3% (74/101) reported a decline in their memory or thinking, 
72.5% (74/102) had restless sleep, and 77.4% (27/35) had experi-
enced a change in their balance or walking.
The onset of anosmia, memory decline, and sleep disturbance 
were all more likely to precede the onset of EH in our cohort 
(p <  0.001, p =  0.002, and p =  0.002, respectively), but there 
was no clear temporal relationship between the onset of EH and 
the onset of motor symptoms (p = 0.221) in line with the above 
finding of a lack of association between EH and disease duration 
(Table 4).
relationship Between eh and Vh
In 52.8% (19/36) of reported cases, EH onset was described as 
occurring around the same time as VH, with 25% (9/36) and 
22.2% (8/36), respectively, reporting EH onset before and after 
VH onset. This finding reached statistical significance (p = 0.046) 
(Table 4).
A major overlap was observed between those reporting VH 
and those reporting EH (Figure 2); 85.9% of those with VH also 
had EH. Those who reported EH were significantly more likely 
to report VH (26.6%, 55/207) than those who did not report EH 
(4.4%, 9/204) (p < 0.001) (Table 4). About 37.0% (152/411) of all 
respondents reported EH but no VH, and 2.2% (9/411) reported 
VH but no EH (Figure 2).
TaBle 3 | characteristics of reported extracampine hallucinations (eh).
Feature Observed 
result (%)
p-Value*
Laterality Front 11 (6.4) <0.001
Behind 7 (4.1)
Side 153 (89.5)
No laterality 88 (53.0) 0.438
Left/right preference 78 (47.0)
 Left† 31(39.7)† 0.007†
 Right† 47 (60.3)†
Familiarity Familiar 34 (34.0) <0.001
Unfamiliar 66 (66.0)
Emotional 
content
For “a feeling of movement”
Pleasant 3 (1.6) <0.001
Unpleasant 33 (17.5)
Neither pleasant nor unpleasant 153 (81.0)
For “the sense of a presence”
Pleasant 10 (9.8) <0.001
Unpleasant 24 (23.5)
Neither pleasant nor unpleasant 68 (66.7)
Happy 2 (1.1) <0.001
Sad 7 (3.7)
Neither 180 (95.2)
EH content Animals 20 (20.2) <0.001
People 70 (70.7)
Inanimate objects 9 (9.1)
Other 
sensory 
components
Auditory component 6 (5.9) <0.001
No auditory component 95 (94.1)
Tactile component 11 (10.9) <0.001
No tactile component 90 (89.1)
Stereotyped Always the same 29 (29.6) <0.001
Not always the same 69 (72.6)
Timing Occur at a particular time of day 
(morning/afternoon/evening/night)
49 (26.2) <0.001
Occur at any time of day or night 138 (73.8)
*Chi-squared testing.
†Subgroup analysis.
Bold font denotes statistically significant results with a cut off of p < 0.05.
TaBle 2 | a comparison of participants with and without extracampine 
hallucinations (eh).
Participants 
with eh
Participants 
without eh
p-Value
Number of respondents 208 (50.4) 204 (49.6) –
Female respondents (%) 107 (54.0) 91 (46.0) 0.165*
Age (years) (SD) 62.1 (8.1) 61.6 (8.3) 0.520†
Visual hallucinations 
reported (%)
55/207 (26.6) 9/204 (4.4) <0.001*
Disease duration (years) (SD) 7.5 (5.0) 7.1 (4.9) 0.158‡
Hoehn and Yahr Stage (%) 0.002§
 Stage 1 67 (32.2) 87 (42.9)
 Stage 2 35 (16.8) 47 (23.2)
 Stage 3 96 (46.2) 59 (29.1)
 Stage 4 10 (4.8) 8 (3.9)
 Stage 5 0 (0) 2 (1.0)
*Chi squared test.
†Independent T-test.
‡Mann–Whitney U.
§Chi squared test with trend (Hoehn and Yahr classes collapsed to Stage 1, Stage 2, 
and Stage ≥ 3).
Bold font denotes statistically significant results with a cut off of p < 0.05.
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Predictors of eh
A binary logistic regression was performed to ascertain the 
effects of age, gender, disease duration, disease severity (Hoehn 
and Yahr score), and the presence of VH on the likelihood that 
the participants had experienced EH. The logistic regression 
model was statistically significant [χ2(5) = 44.463, p < 0.001] 
and explained 13.9% (Nagelkerke R2) of the variance in the 
presence of EH. Overall, it correctly predicted the occurrence 
or absence of EH in 62.4% of respondents; it correctly classi-
fied 37.9% of those experiencing EH and 87.1% of those not 
experiencing EH. Of these variables, only the presence of VH 
was found to be significantly predictive of EH occurrence 
(Table 4).
Medication
Participants who had experienced EH were asked if their medica-
tions made their EH better or worse. Overall medications did not 
appear to have an effect upon EH (p < 0.001) with 72.6% (69/95) 
of respondents stating they had not noticed an effect.
27.4% (26/95) reported that their medication had affected their 
EH and provided further data regarding individual drugs (Table 4). 
The following data were collected only from these 26 participants 
therefore the number of responses for each drug was small. For 
some drugs (co-benyldopa, stalevo, benzotropine, trihexyphenidyl, 
entacapone, rivastigmine, donepezil, and galantamine), informa-
tion was obtained from fewer than five respondents, and these small 
sample sizes precluded meaningful interpretation; for example, 
only three patients in this subgroup were taking rivastigmine. Of 
the remaining drugs, 13/17 respondents stated that pramipexole 
significantly worsened EH (p = 0.010). No significant drug effect 
on EH was noted for other drugs (Table 4).
Test–retest reproducibility of responses
52.9% (301/569) of participants completed a retest phase in which 
they retook an identical questionnaire. Analysis of this data by 
patientslikeme® indicated that our questionnaire had a high 
test–retest reliability (Cronbachs α = 0.94).
DiscUssiOn
The prevalence of EH in patients with PD, their characteristics 
and association with other key clinical features of PD were 
investigated using a web-based questionnaire circulated to the 
online patient community patientslikeme®. To the best of our 
knowledge, this is the first large cross-sectional study to focus on 
the occurrence of EH in patients with PD. The main finding of 
the study was that EH were reported by over 50% of respondents, 
representing a prevalence more than three times greater than 
that of VH (50.4 versus 15.5%). Although there is no prior study 
specifically exploring the prevalence of EH in PD against which 
these study results can be compared, this 50.4% prevalence figure 
falls within the range of reported prevalences of minor hallucina-
tions in PD (4, 19–21), which includes EH.
Extracampine hallucinations were significantly more likely 
to be experienced as a presence alongside, rather than behind, 
the individual (p <  0.001), to be an unfamiliar rather than a 
familiar presence (p <  0.001), for the presence to be that of a 
TaBle 4 | relationships between (a) the onset of eh and other PD symptoms, (B) eh and potential predictor variables, and (c) eh and medication.
(a) Temporal relationships between the onset of eh and other PD symptoms
symptom Before eh (%) after eh (%) coincides with eh (%) p-Value*
VH 9 (22.0) 8 (26.8) 9 (51.2) 0.046
Anosmia 57 (86.4) 9 (13.6) † <0.001
Memory decline 44 (69.8) 19 (30.2) † 0.002
Sleep disturbance 44 (69.8) 19 (30.2) † 0.002
Motor symptoms 15 (62.5) 9 (37.5) † 0.221
(B) Predictors of the occurrence of eh on a logistic regression analysis
Variable coefficient se Odds ratio 95% confidence limits p-Value
Age 0.006 0.013 0.994 0.981 1.032 0.644
Sex 0.213 0.212 1.273 0.817 1.873 0.315
Disease duration −0.002 0.023 0.927 0.955 1.043 0.927
H&Y score 0.162 0.114 1.176 0.941 1.470 0.154
VH 1.958 0.380 7.083 0.067 0.297 <0.001
(c) Medication effect on eh (data from 26/95 participants whose medication affected eh)
Medication number of responders eh better (%) eh worse (%) no effect (%) p-Value*
Co-careldopa 24 8 (33) 5 (21) 11 (46) 0.325
Rotigotine 7 0 (0) 4 (57) 3 (42) 0.160
Pramipexole 17 1 (6) 13 (76) 3 (18) 0.010
Ropinirole 18 2 (11) 9 (50) 7 (39) 0.229
Selegiline 7 0 (0) 2 (29) 5 (71) 0.066
Rasagiline 12 0 (0) 1 (8) 11 (92) <0.001
Amantadine 12 3 (25) 4 (33) 5 (42) 0.779
EH, extracampine hallucinations; VH, visual hallucinations.
*Chi squared testing.
†Data not requested on the questionnaire.
Bold font denotes statistically significant results with a cut off of p < 0.05.
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person rather than an animal or inanimate object (p <  0.001), 
and to be emotionally neutral in content (p < 0.001). EH did not 
tend to be stereotypical in nature (p < 0.001), and did not tend 
to have an auditory or tactile component (p < 0.001). There was 
no significant association between occurrence of EH and time of 
day (p < 0.001).
With regard to other aspects of PD, there was a statistically 
significant (p = 0.002) association between EH occurrence and 
disease severity, as measured by the Hoehn and Yahr stage, but 
not with respondent age, gender, and disease duration of PD. 
The presence of VH was predictive of EH and the majority of 
respondents who reported EH also described VH (85.9%). In 
over 50% of respondents, EH and VH onset occurred around 
the same time.
Surprisingly, and in contrast to previous studies reporting that 
the onset of VH was predictive of future cognitive decline, in this 
study respondents stated that EH occurred after the onset of cogni-
tive problems, as well as after anosmia and sleep disturbance. This 
was an unexpected finding. One possibility is that these results 
may be skewed by the greater difficulty in recognizing the onset 
of EH, given its current under-reporting and under-recognition. 
However, another possibility is that the Lewy body pathology 
may affect the cortical systems underpinning EH later than those 
involved in cognition. That said, this would seem a less plausible 
explanation when the neural substrate of EH is considered. While 
this is yet to be established, given that EH represent percepts that 
are by definition devoid of any visual form, it is probable that 
they are of cortical origin rather than indicative of a disorder of 
primary sensory pathways. This is reinforced by a recent study 
investigating the imaging changes associated with the “sense of a 
presence,” both in a small cohort of patients with neurological dis-
orders (epilepsy, stroke but no PD patients) and healthy subjects 
in whom this phenomenon was induced artificially using syn-
chronous and asynchronous stimulation (37). The brain regions 
most commonly associated with “the sense of a presence” were the 
frontoparietal cortex, insular cortex, and temporoparietal cortex. 
With regard to the latter, the clinicopathological observation that 
VH in Lewy body disease were strongly associated with a high 
density of Lewy bodies in the temporal lobe (9) may provide a 
clue as to the cortical substrate of EH. Given that, the onset of 
VH commonly precedes that of cognitive impairment in PD, 
the expectation might have been that the latter would also be 
preceded by the occurrence of EH. This will need to be clarified 
by way of future prospective natural history studies of EH in PD 
patients without cognitive impairment.
Insufficient data were generated to draw any firm conclusions 
regarding the effect of medications on EH. Although the major-
ity of patients reported that their medications did not influence 
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their EH, a minority did notice an effect with the only significant 
finding being that pramipexole worsened EH.
This study has limitations. The use of a web-based question-
naire to obtain responses from an online community of patients 
not diagnosed, or under the care of, the study authors means that 
there is no mechanism to confirm the diagnosis of PD or the Hoehn 
and Yahr score. Knowledge is also lacking on the demographic 
details of the respondent group and given the online nature of 
both the community and the questionnaire, it is possible that the 
respondents as group may not reflect the entire socio-economic 
breadth of the wider PD patient population. Additionally, this 
study is potentially vulnerable to the biases associated with all 
questionnaire-based research studies (selection, recall, and 
responder bias). With regard to disease severity of the study 
respondents, the mean Hoehn and Yahr score was 2.1, which 
may reflect the fact that patients with more severe disease could 
find completing online questionnaires more challenging. Finally, 
in order to ensure some degree of homogeneity among the test 
population, this study did not obtain responses from patients with 
PD dementia (PDD) and DLB, and no data are currently available 
regarding the prevalence of EH in the general population.
Future research will aim to determine the prognostic sig-
nificance of EH, notably with regard to predicting later cognitive 
decline, as well as to establish the prevalence of EH in patients 
with PDD and Lewy body dementia.
cOnclUsiOn
The occurrence of EH in 50.4% of respondents suggests that EH 
is an under-reported and under-recognized symptom of PD. 
Given that, the occurrence of VH represents one of the core 
criteria for the diagnosis both of PDD and DLB, identification 
of EH may be of high clinical significance The likely neural 
substrate of this phenomenon suggests that EH may indicate 
cortical involvement in PD and thus be predictive of future 
cognitive decline.
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